Studies from University of Turku describe new findings in arthritis risk factors
2007 NOV 12 -- Current study results from the report, 'Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict synergistically the development of seropositive rheumatoid arthritis,' have been published. In this recent article published in the journal Annals of the Rheumatic Diseases, scientists in Finland conducted a study "To find out whether autoantibodies to citrullinated telopeptides of type I and II collagens and to cyclic citrullinated peptides (CCPs) predict the development of rheumatoid arthritis (RA) A case-control study (matched for sex, age and municipality) was nested within a Finnish cohort of 19072 adults who had neither arthritis nor a history of it at the baseline examination during 1973-7. 124 subjects developed RA by late 1989, and of these, 89 were positive for rheumatoid factor (RF). Preillness serum specimens were analysed for autoantibodies against arginine (A)-or citrulline (C)-containing synthetic telopeptides using a chemiluminescence method and for anti-CCPs Mark2 with an enzyme-linked immunosorbent assay method The mean levels of autoantibodies to citrulline-containing telopeptides and the C/A ratios of type I and II collagens and to CCP were higher in subjects who later developed RF-positive RA." "In the highest tertiles of C/A (I), C/A (II) ratios and anti-CCPs levels, the relative risk of RF-positive RA was significantly increased. In the multifactorial model, only anti-CCPs retained its statistical significance. However, the interaction term of C/A (II) ratio and anti-CCPs proved to be statistically significant (p=0.02). The subjects ranked into the highest tertiles of both C/A (II) ratio and anti-CCPs had an odds ratio of 20.06 (95% confidence interval, 4.37 to 92.06) of developing RF-positive RA compared with those in the lowest tertiles of these antibodies," wrote M.K. Koivula and colleagues, University of Turku. The researchers concluded: "None of the autoantibodies predicted RF-negative RA Autoantibodies to citrullinated telopeptides of type I and II collagen and to CCPs exert a synergistic effect on the risk of seropositive RA." Koivula and colleagues published their study in Annals of the Rheumatic Diseases (Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict synergistically the development of seropositive rheumatoid arthritis. Annals of the Rheumatic Diseases, 2007;66(11):1450-5). Additional information can be obtained by contacting M.K. Koivula, University of Oulu and University of Turku, Dept. of Clinical Chemistry, Oulu and Turku, Finland. The publisher of the journal Annals of the Rheumatic Diseases can be contacted at: B M J Publishing Group, British Med Association House, Tavistock Square, London WC1H 9JR, England. Keywords: Finland, Arthritis Risk Factors, Amino Acid, Arthritis, Citrulline, Clinical Trial Research, Dietary Supplement, Micronutrient, Rheumatic Disease, Rheumatoid Arthritis. This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2007, Pain & Central Nervous System Week via NewsRx.com.
|
